MEDIPOST announced on the 17th that it has enrolled and treated the first patient participating in the Phase 1 clinical trial of the injectable cell therapeutic (code named SMUP-IA-01) for the treatment of knee osteoarthritis treatment on the 14th.
The clinical trial, being conducted at Seoul National University Hospital, will enroll patients with early to mid-stage (K&L grade 2-3) knee osteoarthritis and following a single intra-articular injection, the safety and potential efficacy will be assessed.
The follow-up period is 6 months post-treatment and the participants will be divided into three dosing groups: low dose, medium dose and high dose.
A MEDIPOST official said that the injectable cell therapeutic (code named SMUP-IA-01) is the first product utilizing the SMUP-Cell platform, a next-generation stem cell culture technology developed independently by MEDIPOST, and is highlighted by the ability to select and produce highly effective stem cells in large quantities.”
In addition, transportation and storage has been made easy with frozen final product formulation, which will be advantageous for the global market in terms of logistics. The frozen formulation is expected to be extremely useful in the development of cell therapeutics targeting various incurable diseases.
The development of the SMUP-Cell technology and SMUP-IA-01 – an injectable therapeutic for osteoarthritis, has been supported by the “High-Tech Biopharmaceutical Global Technology Development Project” co-funded by the Ministry of Health and Welfare and the Ministry of Science and ICT.
